Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

1.

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T.

N Engl J Med. 1995 Apr 27;332(17):1132-6.

PMID:
7700286
[PubMed - indexed for MEDLINE]
Free Article
2.

Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.

Michiels JJ.

Clin Appl Thromb Hemost. 1999 Oct;5(4):247-51. Review.

PMID:
10726022
[PubMed - indexed for MEDLINE]
3.

Therapeutic options for essential thrombocythemia and polycythemia vera.

Solberg LA Jr.

Semin Oncol. 2002 Jun;29(3 Suppl 10):10-5. Review.

PMID:
12096352
[PubMed - indexed for MEDLINE]
4.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.

N Engl J Med. 2005 Jul 7;353(1):33-45.

PMID:
16000354
[PubMed - indexed for MEDLINE]
Free Article
5.

The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.

Treliński J, Tybura M, Smolewski P, Robak T, Chojnowski K.

Blood Coagul Fibrinolysis. 2009 Dec;20(8):646-51. doi: 10.1097/MBC.0b013e32832f6c5b.

PMID:
19741509
[PubMed - indexed for MEDLINE]
6.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators.

N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.

PMID:
16531616
[PubMed - indexed for MEDLINE]
Free Article
7.

Thrombotic and hemorrhagic complications in chronic myeloproliferative disorders.

Sagripanti A, Ferretti A, Nicolini A, Carpi A.

Biomed Pharmacother. 1996;50(8):376-82.

PMID:
8952859
[PubMed - indexed for MEDLINE]
8.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.

De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T; GIMEMA CMD-Working Party.

Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11.

PMID:
18268279
[PubMed - indexed for MEDLINE]
Free Article
9.

Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.

Randi ML, Rossi C, Fabris F, Girolami A.

Clin Appl Thromb Hemost. 2000 Jan;6(1):31-5.

PMID:
10726046
[PubMed - indexed for MEDLINE]
10.

Acute coronary disease in essential thrombocythemia and polycythemia vera.

Rossi C, Randi ML, Zerbinati P, Rinaldi V, Girolami A.

J Intern Med. 1998 Jul;244(1):49-53.

PMID:
9698024
[PubMed - indexed for MEDLINE]
11.

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.

Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T.

Ann Hematol. 2001 Feb;80(2):74-8.

PMID:
11261328
[PubMed - indexed for MEDLINE]
12.

Initial experience with dual antiplatelet thromboprophylaxis using clopidogrel and aspirin in patients with mechanical aortic prostheses.

García-Rinaldi R, Carro-Pagán C, Schaff HV, McKellar SH, Thompson JL 3rd, Quiñones J, Rodríguez-Acosta JF.

J Heart Valve Dis. 2009 Nov;18(6):617-25; discussion 626.

PMID:
20099710
[PubMed - indexed for MEDLINE]
13.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

PMID:
15461876
[PubMed - indexed for MEDLINE]
Free Article
14.

Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?

Ruggeri M, Castaman G, Rodeghiero F.

Haematologica. 1993 Nov-Dec;78(6 Suppl 2):18-21.

PMID:
8039753
[PubMed - indexed for MEDLINE]
15.

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.

Finazzi G, Ruggeri M, Rodeghiero F, Barbui T.

Br J Haematol. 2000 Sep;110(3):577-83.

PMID:
10997967
[PubMed - indexed for MEDLINE]
16.

Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia.

Michiels JJ, van Genderen PJ, Lindemans J, van Vliet HH.

Leuk Lymphoma. 1996 Sep;22 Suppl 1:47-56. Review.

PMID:
8951772
[PubMed - indexed for MEDLINE]
18.

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE.

N Engl J Med. 1998 Dec 3;339(23):1665-71.

PMID:
9834303
[PubMed - indexed for MEDLINE]
Free Article
19.
20.

Clinical course of essential thrombocythemia in 147 cases.

Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F.

Cancer. 1990 Aug 1;66(3):549-56.

PMID:
2364366
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk